Agile Therapeutics to report on new generation of transdermal contraceptives

Apr 24 2007

Dr. Thomas M. Rossi, President and Chief Executive Officer of Agile Therapeutics, Inc., will report on the company's progress in developing a new generation of transdermal contraceptives at the BIO 2007 annual international conference on biotechnology.

Agile is an early stage Women's Healthcare company, whose low estrogen dose, seven-day transdermal contraceptive patch is currently in phase 2 clinical development.

The BIO 2007 conference will be held at the Boston Convention and Exhibition Center in Boston, MA on May 6 - May 9th, 2007. Dr. Rossi is scheduled to present at 9:30 am in Room C.

Agile Therapeutics is privately held and supported by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is managing over $875 million; the Hillman Company and its Affiliates, a diversified investment firm active in venture capital investing for over 25 years; TL Ventures, with over $1.4 billion under management; and PA Early Stage Partners, with more than $235 million under management.